KG
CRSP icon

Kilter Group’s CRISPR Therapeutics CRSP Stock Holding History

Kilter Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$286 Sell
6
-2
-25% -$105 ﹤0.01% 1440
2025
Q4 		$420 Hold
8
– – ﹤0.01% 1213
2025
Q3 		$519 Hold
8
– – ﹤0.01% 1050
2025
Q2 		$390 Buy
+8
New +$310 ﹤0.01% 1022

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kilter Group's CRSP Position: Q1 2026 in Review

Kilter Group reduced its CRISPR Therapeutics (CRSP) stake by 25% in Q1 2026, selling an estimated $105 and leaving 6 shares worth $286. The position accounts for ﹤0.01% of the portfolio, ranked #1440.

Kilter Group first reported a position in CRSP in Q2 2025 and has held it in 4 quarters since. The position peaked at $519 in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Kilter Group held 6 shares of CRISPR Therapeutics worth $286 as of Q1 2026.
  • Kilter Group sold 2 CRISPR Therapeutics shares in Q1 2026, an estimated $105.
  • CRISPR Therapeutics made up ﹤0.01% of Kilter Group's portfolio in Q1 2026, its #1440 holding.
  • Kilter Group first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Kilter Group's CRISPR Therapeutics position peaked at $519 in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Kilter Group's 13F filing for Q1 2026, filed 14 May 2026.